Press Releases for DDSS

Press Releases
Hercules Technology Growth Capital Announces Three Portfolio Companies That Reached Multi-Million Dollar Milestones
Labopharm's response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
Labopharm comments on judgment in Purdue patent litigation
Labopharm submits response to FDA for novel antidepressant
Labopharm files New Drug Submission with Health Canada for novel antidepressant
Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
InvestorSoup.com Issues Trading Outlook for Labopharm Inc.
Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
Labopharm amends debt facility agreement with Hercules
Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
Labopharm announces details for first quarter results conference call and annual meeting
Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Labopharm to present at Cowen 29th Annual Health Care Conference
Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
Labopharm Comments on Recent Trading Activity - PR Newswire
Labopharm Comments on Recent Trading Activity - CNW
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder - PR Newswire
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder - CNW
Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA - PR Newswire
Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA - CNW
Labopharm announces change to Board of Directors - PR Newswire
Labopharm Reports Results for Third Quarter Fiscal 2008
Labopharm Reports Results for Third Quarter Fiscal 2008
Labopharm announces change to Board of Directors - CNW
Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET) - PR Newswire
Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET) - CNW
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
Nephros Appoints James S. Scibetta as Chairman of Board of Directors
Labopharm to present at CIBC World Markets 7th Annual Eastern Institutional Investor Conference - PR Newswire
Labopharm to present at CIBC World Markets 7th Annual Eastern Institutional Investor Conference - CNW
Labopharm to present at Canaccord Adams 28th Annual Global Growth Conference
Labopharm reports results for second quarter fiscal 2008
Labopharm reports results for second quarter fiscal 2008
Labopharm's Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Labopharm's Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) - PR Newswire
Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) - CNW
FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response - PR Newswire
FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response - CNW
Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product - PR Newswire
Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product - CNW
Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
Labopharm Reports Results for First Quarter Fiscal 2008 - Jun 1 2008 5:29PM
Labopharm announces details for first quarter results conference call and annual meeting - Jun 1 2008 5:29PM
Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy